The 3 analysts offering 12-month price forecasts for Adverum Biotechnologies Inc have a median target of 3.00, with a high estimate of 6.00 and a low estimate of 3.00. The median estimate represents a +144.90% increase from the last price of 1.23.
The current consensus among 4 polled investment analysts is to Hold stock in Adverum Biotechnologies Inc. This rating has held steady since March, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.34
Reporting Date Aug 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.